15 Feb APOLLO Trials Support Potential Role of Ultra-Low-Dose Triple Therapy as Initial Strategy for Mild-to-Moderate Hypertension

MedicalResearch.com Interview with:

Prof. Moo-Yong Rhee

Professor Moo-Yong Rhee MD, PhD.
Cardiology, Dongguk University Ilsan Hospital
College of Medicine, Dongguk University
Goyang-si, Gyeonggi-do, Korea

MedicalResearch.com: What is the background for this study?

Response: Hypertension remains one of the leading causes of cardiovascular morbidity and mortality worldwide. Major challenges in its initial treatment include therapeutic inertia, reliance on stepwise dose escalation of single agents, and reduced adherence due to dose-related adverse effects. These limitations often delay optimal blood pressure control.

To address these issues, the concept of low-dose combination therapy was proposed, based on the rationale that combining multiple agents at lower doses may enhance efficacy while minimizing side effects. Although several studies have supported this concept, systematic translational research and confirmatory clinical trials were needed before widespread clinical implementation.

The recently completed APOLLO-301 and APOLLO-302 trials were confirmatory, randomized, phase 3 studies designed to evaluate the efficacy and safety of a single-pill ultra-low-dose triple combination therapy, conducted in accordance with regulatory standards. This formulation combined three antihypertensive agents (amlodipine (1.67 mg), losartan (16.67 mg), and chlorthalidone (4.17 mg)) each at approximately one-third of its standard dose. The triple combination was directly compared with standard-dose monotherapy (amlodipine 5 mg or losartan 50 mg).

After 8 weeks of treatment, the ultra-low-dose triple combination achieved blood pressure reductions comparable to those of amlodipine 5 mg and significantly greater than those of losartan 50 mg, while maintaining good tolerability. These findings support the potential role of ultra-low-dose triple therapy as an effective initial treatment strategy for patients with mild-to-moderate hypertension.

MedicalResearch.com: Does the cost of the medication or monitoring differ among the two groups?

Response: Medication costs vary across countries depending on national pricing policies and insurance systems, making direct international comparisons difficult. In South Korea, the single-pill ultra-low-dose triple combination is priced at approximately 593 KRW (about USD 0.41) per tablet, corresponding to a monthly cost of around USD 11.

In our study, approximately 60% of patients with mild-to-moderate hypertension achieved blood pressure control with this therapy. If similar results are replicated in routine practice, many patients may reach target blood pressure without requiring dose escalation or additional medications, potentially limiting overall treatment costs.

From a global health perspective, this cost profile may be particularly relevant for low- and middle-income countries. A simplified, affordable single-pill strategy could improve access to effective blood pressure control and may ultimately help reduce cardiovascular risk at the population level.

In addition, in primary care settings, especially in resource-limited environments, individualized selection of multiple agents targeting distinct pathophysiological mechanisms may be challenging. The ultra-low-dose triple combination simultaneously targets three major mechanisms of hypertension while minimizing dose-related adverse effects. This may reduce treatment complexity and enable a more practical, scalable initial treatment approach.

MedicalResearch.com: What are the main findings?

Response:  In our study, a single-pill ultra-low-dose triple combination achieved effective blood pressure reduction with good tolerability, comparable to standard-dose amlodipine 5 mg monotherapy and superior to losartan 50 mg, in patients with mild-to-moderate hypertension.

Rather than relying solely on stepwise dose escalation of single agents, initiating therapy with multiple agents at very low doses may provide a practical and potentially more efficient approach to achieving timely blood pressure control. While further studies are needed to confirm long-term cardiovascular outcomes, this strategy may offer a promising alternative framework for the initial treatment of hypertension.

MedicalResearch.com: What should readers take away from your report?

Response: In our study, a single-pill ultra-low-dose triple combination achieved effective blood pressure reduction with good tolerability, comparable to standard-dose amlodipine 5 mg monotherapy and superior to losartan 50 mg, in patients with mild-to-moderate hypertension.

Rather than relying solely on stepwise dose escalation of single agents, initiating therapy with multiple agents at very low doses may provide a practical and potentially more efficient approach to achieving timely blood pressure control. While further studies are needed to confirm long-term cardiovascular outcomes, this strategy may offer a promising alternative framework for the initial treatment of hypertension.

MedicalResearch.com: What recommendations do you have for future research as a results of this study?

Response: Our findings support the potential role of ultra-low-dose triple combination therapy as an initial strategy for hypertension management. However, several key questions remain to be addressed.

First, while our study demonstrates effective blood pressure reduction and good tolerability, it remains essential to determine whether early initiation of ultra-low-dose triple therapy translates into reductions in major cardiovascular events and mortality. Accordingly, cardiovascular outcome trials in high-risk populations, such as patients with established cardiovascular disease, diabetes, or chronic kidney disease, are warranted.

Second, pragmatic real-world studies in primary care settings are needed. Future research should evaluate whether initiating treatment with a single-pill ultra-low-dose triple combination within a simplified, protocolized approach improves long-term adherence, treatment persistence, and overall blood pressure control in general routine practice.

Third, equity-focused research is important. If made affordable, low- or ultra-low-dose triple combination therapy may offer a cost-effective strategy for improving blood pressure control in low- and middle-income countries or underserved populations. Studies assessing affordability, access, supply-chain feasibility, and cost-effectiveness could help determine its potential public health impact.

MedicalResearch.com: Is there anything else you would like to add? Any disclosures?

Response:  The study received industry support from Hanmi Pharm. Co., Ltd. (Korea). Full disclosures are provided in the original publication.

Citation:

Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate Hypertension
February 2026Journal of the American College of Cardiology
DOI:10.1016/j.jacc.2025.12.028

—-

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition.
Some links may be sponsored. Products, services and providers are not warranted or endorsed.
Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on February 15, 2026 by Marie Benz MD FAAD